Group 1 - The core viewpoint of the article highlights the opportunities for the health consumption sector in China due to the aging population and supportive government policies, as outlined in the "Action Plan for Promoting Healthy Consumption" released by 12 departments including the Ministry of Commerce and the National Health Commission [1] - The discussion at the "European Forum" in Paris emphasized the rapid development of China's medical innovation sector and the unique opportunities for Sino-European cooperation in healthcare, as stated by former French Health Minister Olivier Véran [1][3] - Véran noted that cooperation between China and Europe could lead to both regions becoming long-term partners and global leaders in healthcare, with China needing access to European markets and Europe seeking to deepen connections with Chinese innovation resources [1][3] Group 2 - Olivier Dessajan, CEO of High Life China and President of the French Health Industry Alliance, expressed the importance of collaboration with China, stating that not engaging with China would be a mistake [3] - The establishment of high-end medical service nursing homes in cities like Guangzhou, Hangzhou, and Shenzhen by High Life China reflects the adaptation to local regulations while incorporating French operational mechanisms [3] - The CEO of Pro Pharma, Zhu Fangmeng, emphasized the significance of Sino-European cooperation in innovation and manufacturing, noting that nearly one-third of their overseas market is in Europe [3] Group 3 - The discussion highlighted the advanced technologies available in France and Europe, such as confocal endoscopy and radiofrequency ablation devices, while China leads in AI-assisted treatments and clinical trial results [4] - Véran pointed out the important reforms China has made to facilitate the entry of biopharmaceutical companies into the European market, particularly in modernizing drug regulations and accelerating clinical trials [4] - The strategy for AI application in healthcare should balance caution and innovation to promote harmonious economic relations and public interest between China and Europe, according to Véran [4]

21世纪经济报道记者唐唯珂广州报道 电生理类耗材集采继续扩围。 4月中下旬，四川省医疗保障局发布公告，表示将开展四川省电生理类医用耗材带量联动采购。 根据公告，本次医用耗材分组采购需求量原则上不低于同分组历史采购量的80%，采购周期为2年。采 购周期内，如该耗材纳入国家集中带量采购，则本次中选结果执行至全省落实国家中选结果之日，相关 约定采购量按序时进度进行考核。 企业报价及中选产品确定原则方面，四川要求企业报价应不高于全国省级平台最低挂网价(若有)。若产 品在过往省级或省际联盟集采中中选过，只需报价不高于历史最低中选价即拟中选。 对于未曾中选过的申报产品，企业在本次集采中若有本企业同分组其他曾中选产品，报价不高于曾中选 最低价格即可中选；若无本企业同分组其他曾中选产品，企业报价不高于省级或省际联盟集采中同分组 曾中选最低价格算术平均价可中选。 电生理类医用耗材此前已经历过大型联盟集采降价。政策的催化下，电生理产品降价的同时，也有望获 得更多的增量市场份额。本次四川集采仅要求企业报价不高于历史最低中选价，对行业来说较为温和， 属于积极信号。其中，国产企业能在本次集采中中标多少、行业竞争格局能有多少变化是业内关 ...